Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 275

1.

A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea.

DuPont HL, Jiang ZD, Okhuysen PC, Ericsson CD, de la Cabada FJ, Ke S, DuPont MW, Martinez-Sandoval F.

Ann Intern Med. 2005 May 17;142(10):805-12. Erratum in: Ann Intern Med. 2005 Aug 2;143(3):239.

PMID:
15897530
2.

Summaries for patients. Can a new antibiotic safely prevent travelers' diarrhea?

[No authors listed]

Ann Intern Med. 2005 May 17;142(10):I30. No abstract available.

PMID:
15897526
3.

Prevention of travelers' diarrhea with rifaximin in US travelers to Mexico.

Martinez-Sandoval F, Ericsson CD, Jiang ZD, Okhuysen PC, Romero JH, Hernandez N, Forbes WP, Shaw A, Bortey E, DuPont HL.

J Travel Med. 2010 Mar-Apr;17(2):111-7. doi: 10.1111/j.1708-8305.2009.00385.x.

4.

Efficacy of rifaximin in prevention of travelers' diarrhea: a meta-analysis of randomized, double-blind, placebo-controlled trials.

Hu Y, Ren J, Zhan M, Li W, Dai H.

J Travel Med. 2012 Dec;19(6):352-6. doi: 10.1111/j.1708-8305.2012.00650.x. Epub 2012 Sep 14.

5.

Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea.

DuPont HL, Ericsson CD, Mathewson JJ, Palazzini E, DuPont MW, Jiang ZD, Mosavi A, de la Cabada FJ.

Digestion. 1998 Nov-Dec;59(6):708-14.

PMID:
9813398
6.

A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea.

Taylor DN, Bourgeois AL, Ericsson CD, Steffen R, Jiang ZD, Halpern J, Haake R, Dupont HL.

Am J Trop Med Hyg. 2006 Jun;74(6):1060-6.

PMID:
16760520
7.

A randomized, double-blind, pilot study of rifaximin 550 mg versus placebo in the prevention of travelers' diarrhea in Mexico during the dry season.

Flores J, Dupont HL, Jiang ZD, Okhuysen PC, Melendez-Romero JH, Gonzalez-Estrada A, Carrillo I, Paredes M.

J Travel Med. 2011 Sep-Oct;18(5):333-6. doi: 10.1111/j.1708-8305.2011.00549.x. Epub 2011 Aug 1.

8.

Doxycycline prophylaxis of travelers' diarrhea in Honduras, an area where resistance to doxycycline is common among enterotoxigenic Escherichia coli.

Sack RB, Santosham M, Froehlich JL, Medina C, Orskov F, Orskov I.

Am J Trop Med Hyg. 1984 May;33(3):460-6.

PMID:
6375407
9.

A randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of rifaximin for the prevention of travelers' diarrhea in US military personnel deployed to Incirlik Air Base, Incirlik, Turkey.

Armstrong AW, Ulukan S, Weiner M, Mostafa M, Shaheen H, Nakhla I, Tribble DR, Riddle MS.

J Travel Med. 2010 Nov-Dec;17(6):392-4. doi: 10.1111/j.1708-8305.2010.00462.x.

10.

Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy.

Infante RM, Ericsson CD, Jiang ZD, Ke S, Steffen R, Riopel L, Sack DA, DuPont HL.

Clin Gastroenterol Hepatol. 2004 Feb;2(2):135-8.

PMID:
15017618
11.

Effectiveness of rifaximin and fluoroquinolones in preventing travelers' diarrhea (TD): a systematic review and meta-analysis.

Alajbegovic S, Sanders JW, Atherly DE, Riddle MS.

Syst Rev. 2012 Aug 28;1:39. doi: 10.1186/2046-4053-1-39. Review.

12.

Therapy of travelers' diarrhea with rifaximin on various continents.

Steffen R, Sack DA, Riopel L, Jiang ZD, Stürchler M, Ericsson CD, Lowe B, Waiyaki P, White M, DuPont HL.

Am J Gastroenterol. 2003 May;98(5):1073-8.

PMID:
12809830
13.

Rifaximin: a new treatment for travelers' diarrhea.

Pakyz AL.

Ann Pharmacother. 2005 Feb;39(2):284-9. Epub 2004 Dec 14. Review.

PMID:
15598963
14.

Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases.

Koo HL, DuPont HL.

Curr Opin Gastroenterol. 2010 Jan;26(1):17-25. doi: 10.1097/MOG.0b013e328333dc8d. Review.

15.

Rifaximin treatment of pathogen-negative travelers' diarrhea.

DuPont HL, Haake R, Taylor DN, Ericsson CD, Jiang ZD, Okhuysen PC, Steffen R.

J Travel Med. 2007 Jan-Feb;14(1):16-9.

16.

Antibacterial chemoprophylaxis in the prevention of traveler's diarrhea: evaluation of poorly absorbed oral rifaximin.

DuPont HL, Jiang ZD, Okhuysen PC, Ericsson CD, de la Cabada FJ, Ke S, DuPont MW, Martinez-Sandoval F.

Clin Infect Dis. 2005 Dec 1;41 Suppl 8:S571-6.

PMID:
16267721
17.

Targeting of rifamycin SV to the colon for treatment of travelers' diarrhea: a randomized, double-blind, placebo-controlled phase 3 study.

DuPont HL, Petersen A, Zhao J, Mundt A, Jiang ZD, Miller S, Flores J, Shringarpure R, Moro L, Bagin RG, Ballard ED, Totoritis MC.

J Travel Med. 2014 Nov-Dec;21(6):369-76. doi: 10.1111/jtm.12168.

18.

Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections.

Gerard L, Garey KW, DuPont HL.

Expert Rev Anti Infect Ther. 2005 Apr;3(2):201-11. Review.

PMID:
15918778
19.

Prophylactic doxycycline for travelers' diarrhea: results of a prospective double-blind study of Peace Corps volunteers in Morocco.

Sack RB, Froehlich JL, Zulich AW, Hidi DS, Kapikian AZ, Orskov F, Orskov I, Greenberg HB.

Gastroenterology. 1979 Jun;76(6):1368-73.

PMID:
374178
20.

Effectiveness of rifaximin in prevention of diarrhoea in individuals travelling to south and southeast Asia: a randomised, double-blind, placebo-controlled, phase 3 trial.

Zanger P, Nurjadi D, Gabor J, Gaile M, Kremsner PG.

Lancet Infect Dis. 2013 Nov;13(11):946-54. doi: 10.1016/S1473-3099(13)70221-4. Epub 2013 Sep 4.

PMID:
24012319

Supplemental Content

Support Center